Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

5DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 915019-65-7, Nvp-bez235, Bez235, Nvp-bez 235, Bez-235, 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1h-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile

Molecular Formula

C₃₀H₂₃N₅O

Molecular Weight

469.5 g/mol

InChI Key

JOGKUKXHTYWRGZ-UHFFFAOYSA-N

FDA UNII

RUJ6Z9Y0DT

Dactolisib is an orally bioavailable imidazoquinoline targeting the phosphatidylinositol 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Dactolisib inhibits PI3K kinase and mTOR kinase in the PI3K/AKT/mTOR kinase signaling pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.

1 2D Structure

Dactolisib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile

2.1.2 InChI

InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3

2.1.3 InChI Key

JOGKUKXHTYWRGZ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5

2.2 Other Identifiers

2.2.1 UNII

RUJ6Z9Y0DT

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile

2. 2-methyl-2-(4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-1h-imidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile

3. Bez235

4. Nvp Bez235

5. Nvp-bez235

6. Nvpbez235

2.3.2 Depositor-Supplied Synonyms

1. 915019-65-7

2. Nvp-bez235

3. Bez235

4. Nvp-bez 235

5. Bez-235

6. 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1h-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile

7. Nvpbez235

8. Bez 235

9. Nvp-bez-235

10. Nvp Bez235

11. Bez235 (nvp-bez235)

12. Rtb101

13. Rtb-101

14. Ruj6z9y0dt

15. Nsc-751249

16. Bez235 (nvp-bez235, Dactolisib)

17. Chebi:71952

18. 915019-65-7 (free Base)

19. 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile

20. S1009

21. 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile

22. Nvp-bez235-nx

23. 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile

24. 2-methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile.

25. 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1h-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile

26. Dactolisib [usan]

27. Dactolisib [usan:inn]

28. Unii-ruj6z9y0dt

29. Bez235(nvp-bez235)

30. 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile

31. 2-methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile

32. Kinome_2911

33. Ct-bez

34. Dactolisib (bez235)

35. Dactolisib; Bez-235

36. Dactolisib [inn]

37. Dactolisib (usan/inn)

38. Nvp-bez235, Free Base

39. Mtor Inhibitor, Bez235

40. Dactolisib [who-dd]

41. Schembl143623

42. Gtpl7950

43. Chembl1879463

44. Bdbm92862

45. Amy2877

46. Dtxsid10238599

47. Ex-a404

48. Bcpp000344

49. Hms3244g21

50. Hms3244g22

51. Hms3244h21

52. Hms3672e19

53. Act04718

54. Bcp00216

55. Bez235 - Nvp-bez235

56. Mfcd10565944

57. Nsc751249

58. Nsc755807

59. Nsc800085

60. Zinc24760115

61. Akos005217097

62. Bcp9000397

63. Ccg-207981

64. Cs-0080

65. Db11651

66. Es-0038

67. Nsc 751249

68. Nsc-755807

69. Nsc-800085

70. Pb26555

71. 2-methyl-2-[3-methyl-2-oxo-8-(3-quinolinyl)-1-imidazo[4,5-c]quinolinyl]propanenitrile

72. Dactolisib (bez235, Nvp-bez235)

73. Ncgc00187481-01

74. Ncgc00187481-02

75. Ncgc00187481-04

76. Ncgc00187481-05

77. Ncgc00187481-06

78. Ncgc00187481-15

79. 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile

80. 2-methyl-2-(4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-1h-imidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile

81. Ac-25486

82. Hy-50673

83. Ft-0658563

84. Ec-000.2325

85. D10552

86. J-509915

87. Q4835503

88. Brd-k12184916-001-01-4

89. 1028385-31-0

90. 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)phenyl)propionitrile

91. 2-methyl-2-[4-[3-methyl-2-oxo-8-(3-quinolyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile

92. 4-[2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1h-imidazo[4, 5-c]quinolin-1-yl]-.alpha.,.alpha.-dimethylbenzeneacetonitrile

93. Benzeneacetonitrile, 4-(2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1h-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-

2.4 Create Date

2007-01-03

3 Chemical and Physical Properties

Molecular Formula	C₃₀H₂₃N₅O
Molecular Weight	469.5 g/mol
XLogP3	5.2
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	3
Exact Mass	469.19026037 g/mol
Monoisotopic Mass	469.19026037 g/mol
Topological Polar Surface Area	73.1 Å²
Heavy Atom Count	36
Formal Charge	0
Complexity	872
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Find Dactolisib manufacturers, exporters & distributors on PharmaCompass

Dactolisib

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

5 Drugs in Development

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

5DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?